News
RHHBF
445.00
NaN%
--
Outlook: 'Hold' - Caution On LYTENAVA FDA Approval And Cash Needs
Seeking Alpha · 1h ago
Bicara Therapeutics names Jeremy Bender, Christy Oliger to board
PUBT · 6h ago
CytomX Therapeutics appoints Charles Fuchs to board of directors
PUBT · 1d ago
Weekly Report: what happened at RHHBF last week (0720-0724)?
Weekly Report · 1d ago
Chugai posts transcript of FY2026 Q2 financial results conference call
PUBT · 1d ago
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
Seeking Alpha · 3d ago
Roche launches FDA-cleared PCR test; expands women's health portfolio
Seeking Alpha · 4d ago
ROCHE HOLDING AG - COMMERCIAL LAUNCH OF COBAS BV/CV ASSAY EXPECTED LATER THIS YEAR
Reuters · 4d ago
Roche says EU regulator panel backs Susvimo approval for wet AMD
PUBT · 4d ago
EMA'S CHMP: RECOMMENDS GRANTING MARKETING AUTHORISATION FOR RUXOLITINIB VIATRIS
Reuters · 4d ago
Chugai forecasts FY2026 dividend per share at JPY 132
PUBT · 4d ago
Chugai Pharma FY26 Q2 net income climbs 19.2% to ¥231.7 billion; revenue rises 14.7% to ¥663.3 billion
PUBT · 4d ago
Roche jumps despite reiterating 2026 outlook
Seeking Alpha · 5d ago
Roche Holding Non-GAAP EPS of CHF 10.85, revenue of CHF 30.36B
Seeking Alpha · 5d ago
Roche H1 FY26 IFRS operating profit drops 6% to CHF 9.7 billion; sales fall 2% to CHF 30.4 billion
PUBT · 5d ago
Flatiron Health UK partners with NHS Greater Glasgow and Clyde in Scotland oncology data deal
PUBT · 6d ago
NURIX THERAPEUTICS - CO AND ROCHE TO JOINTLY ADVANCE BEXOBRUTIDEG IN CLL, B-CELL MALIGNANCIES, MS, AND CSU
Reuters · 6d ago
MaxCyte signs multi-platform technology license deal with Genentech to support cell therapy development
PUBT · 07/21 12:08
MAXCYTE - GENENTECH TO ACCESS MAXCYTE EXPERT GTX PLATFORM AND TECHNOLOGIES FOR CELL THERAPY WORKFLOWS
Reuters · 07/21 12:05
Calidi Biotherapeutics adds former Genentech, Celgene executive Corsee Sanders to board
PUBT · 07/21 12:03
More
Webull provides a variety of real-time RHHBF stock news. You can receive the latest news about Roche Hldgs Ag through multiple platforms. This information may help you make smarter investment decisions.
About RHHBF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.